BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 5, 2019
View Archived Issues
Arcturus receives additional support from CF Foundation to develop mRNA therapies to treat CF
Read More
AC Immune initiates phase Ib/IIa study of ACI-35.030 vaccine for the treatment of AD
Read More
VHIO and BST co-launch clinical trial of ViroTCell
Read More
UBL4A acts as an authophagy inhibitor and tumor suppressor in pancreatic ductal adenocarcinoma
Read More
Vacuolar protein sorting 35 is a regulator of tau phosphorylation and neuropathology
Read More
Novel VEGFR-2 inhibitors show significant antiproliferative activity in preclinical models
Read More
Oncoceutics reports phase I data for ONC-201
Read More
Better blood diagnostics with a different Holmes
Read More
A spoonful of sugar helps immunity calm down
Read More
MolMed describes chimeric antigen receptors targeting CD44
Read More
ALDH1 antigen-pulsed dendritic cells created at the University of Michigan
Read More
AC Immune patents agents targeting misfolded human TAR DNA-binding protein 43
Read More
Sosei Heptares and Takeda enter into new strategic partnership
Read More
California Institute of Technology, University of Tennessee present DPAGT1 inhibitors
Read More
Idorsia Pharmaceuticals identifies C5aR antagonists
Read More
Cancer research leads to pregnancy insights
Read More
FDA approves Turalio as first therapy for rare and debilitating joint tumor
Read More
Phase III IMvigor130 study of Tecentriq meets coprimary endpoint
Read More
Trifunctional natural killer cell engagers targeting tumor antigens control tumor growth in vivo
Read More
Pivotal phase III RESET study of rivipansel does not meet primary nor key secondary endpoints
Read More
Positive phase II data presented for dry powder inhaler formulation of ensifentrine
Read More
Analysis of phase III study of masitinib in melanoma carrying a mutation in JM domain of c-Kit
Read More
Telix Pharmaceuticals and DKFZ enter into collaboration agreement for image-guided prostate surgery
Read More
Poxel initiates PK/PD trial as part of its phase IIa clinical program for PXL-770
Read More
